A LASSO Cox Regressio-based Nomogram for Predicting Progression-free Survival in Head and Neck Cancer Treated with Radiotherapy or Chemoradiotherapy

Objective: Head and neck squamous cell carcinoma (HNSCC) is a heterogeneous group of diseases characterized by high rates of recurrence and progression, and TNM staging alone is not always sufficient to predict prognosis.To facilitate individualized predict progression-free survival (PFS) prediction in patients treated with chemoradiotherapy (CRT), we developed a LASSO Cox model using routinely available pretreatment variables and created a nomogram to aid interpretation. Material and Methods:We retrospectively reviewed 192 consecutive HNSCC patients treated with definitive or postoperative radiotherapy (RT)based therapy at our center between December 2010 and October 2023.PFS was the primary endpoint of the study, and LASSO Cox penalized regression was applied for variable selection and coefficient shrinkage.The optimal lambda was determined using 5-fold cross-validation, and the Harrell C-index and receiver operating characteristic (ROC) curves were used to assess discriminatory performance.Calibration was also performed across risk quartiles.A Harrell-type nomogram was constructed.Results: Among 192 patients, the observed PFS follow-up time was 20.3 months (median; interquartile range 10.0-43.9),and the median followup among censored patients was 26.5 months; 60 PFS events (31.3%) were recorded.LASSO Cox regression retained eight stable predictors in the model: Eastern Cooperative Oncology Group performance status [hazard ratio (HR): 1.33], age (HR: 1.24), tumor stage (HR: 1.17), neutrophil-tolymphocyte ratio (HR: 1.16), C-reactive protein (HR: 1.16), lactate dehydrogenase (HR: 1.06), albumin (HR: 1.04), and body mass index category (a protective factor; HR: 0.65).The apparent C-index of the model was 0.666, which decreased to 0.591 after bootstrap optimism correction.In timedependent ROC analysis, the area under the curve (AUC) reached its highest value at 24 months (AUC=0.72).High-risk patients (n=64) had a median PFS of 12.3 months and an event rate of 45.3%, whereas the low-to-intermediate-risk group (n=128) had a median PFS of 26.5 months and an event rate of 24.2% (p<0.0001). Conclusion:The nomogram developed using the LASSO method and routine clinical and biochemical parameters significantly predicted PFS in patients with HNSCC treated with RT/CRT and identified distinct risk groups.By integrating five pathophysiological axes-demographic, functional, tumor burden, inflammatory, and nutritional-into a single tool, this model may provide practical support for clinical decision-making at the bedside; however, it requires confirmation through external, multicenter validation studies.

Authors

Institutions

Publication Details

Journal
Journal of Oncological Sciences
Published
2026-11-13
DOI
https://doi.org/10.37047/jos.galenos.2026.2026-7-6
Primary Topic
Head and Neck Cancer Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

A LASSO Cox Regressio-based Nomogram for Predicting Progression-free Survival in Head and Neck Cancer Treated with Radiotherapy or Chemoradiotherapy

Mehmet Kayaalp, Hatice Bölek, Enes Erul, Hatime Arzu Yaşar
2 links
Journal of Oncological Sciences
Head and Neck Cancer Studies
article

A LASSO Cox Regressio-based Nomogram for Predicting Progression-free Survival in Head and Neck Cancer Treated with Radiotherapy or Chemoradiotherapy

Mehmet Kayaalp, Hatice Bölek, Enes Erul, Hatime Arzu Yaşar
article en

Abstract

Objective: Head and neck squamous cell carcinoma (HNSCC) is a heterogeneous group of diseases characterized by high rates of recurrence and progression, and TNM staging alone is not always sufficient to predict prognosis.To facilitate individualized predict progression-free survival (PFS) prediction in patients treated with chemoradiotherapy (CRT), we developed a LASSO Cox model using routinely available pretreatment variables and created a nomogram to aid interpretation. Material and Methods:We retrospectively reviewed 192 consecutive HNSCC patients treated with definitive or postoperative radiotherapy (RT)based therapy at our center between December 2010 and October 2023.PFS was the primary endpoint of the study, and LASSO Cox penalized regression was applied for variable selection and coefficient shrinkage.The optimal lambda was determined using 5-fold cross-validation, and the Harrell C-index and receiver operating characteristic (ROC) curves were used to assess discriminatory performance.Calibration was also performed across risk quartiles.A Harrell-type nomogram was constructed.Results: Among 192 patients, the observed PFS follow-up time was 20.3 months (median; interquartile range 10.0-43.9),and the median followup among censored patients was 26.5 months; 60 PFS events (31.3%) were recorded.LASSO Cox regression retained eight stable predictors in the model: Eastern Cooperative Oncology Group performance status [hazard ratio (HR): 1.33], age (HR: 1.24), tumor stage (HR: 1.17), neutrophil-tolymphocyte ratio (HR: 1.16), C-reactive protein (HR: 1.16), lactate dehydrogenase (HR: 1.06), albumin (HR: 1.04), and body mass index category (a protective factor; HR: 0.65).The apparent C-index of the model was 0.666, which decreased to 0.591 after bootstrap optimism correction.In timedependent ROC analysis, the area under the curve (AUC) reached its highest value at 24 months (AUC=0.72).High-risk patients (n=64) had a median PFS of 12.3 months and an event rate of 45.3%, whereas the low-to-intermediate-risk group (n=128) had a median PFS of 26.5 months and an event rate of 24.2% (p<0.0001). Conclusion:The nomogram developed using the LASSO method and routine clinical and biochemical parameters significantly predicted PFS in patients with HNSCC treated with RT/CRT and identified distinct risk groups.By integrating five pathophysiological axes-demographic, functional, tumor burden, inflammatory, and nutritional-into a single tool, this model may provide practical support for clinical decision-making at the bedside; however, it requires confirmation through external, multicenter validation studies.

Journal of Oncological Sciences
Ankara University (TR), Ankara Bilkent City Hospital (TR)
Good health and well-being
Head and Neck Cancer Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon